JP2018521999A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521999A5
JP2018521999A5 JP2017568205A JP2017568205A JP2018521999A5 JP 2018521999 A5 JP2018521999 A5 JP 2018521999A5 JP 2017568205 A JP2017568205 A JP 2017568205A JP 2017568205 A JP2017568205 A JP 2017568205A JP 2018521999 A5 JP2018521999 A5 JP 2018521999A5
Authority
JP
Japan
Prior art keywords
protein
fusion protein
hvem
mutation
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017568205A
Other languages
English (en)
Japanese (ja)
Other versions
JP7116285B2 (ja
JP2018521999A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/040108 external-priority patent/WO2017004213A1/en
Publication of JP2018521999A publication Critical patent/JP2018521999A/ja
Publication of JP2018521999A5 publication Critical patent/JP2018521999A5/ja
Priority to JP2021083133A priority Critical patent/JP2021113240A/ja
Priority to JP2022115473A priority patent/JP7559013B2/ja
Application granted granted Critical
Publication of JP7116285B2 publication Critical patent/JP7116285B2/ja
Priority to JP2023210069A priority patent/JP2024019529A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017568205A 2015-06-30 2016-06-29 Ｂｔｌａ融合タンパク質アゴニストおよびその使用 Active JP7116285B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021083133A JP2021113240A (ja) 2015-06-30 2021-05-17 Ｂｔｌａ融合タンパク質アゴニストおよびその使用
JP2022115473A JP7559013B2 (ja) 2015-06-30 2022-07-20 Ｂｔｌａ融合タンパク質アゴニストおよびその使用
JP2023210069A JP2024019529A (ja) 2015-06-30 2023-12-13 Ｂｔｌａ融合タンパク質アゴニストおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187105P 2015-06-30 2015-06-30
US62/187,105 2015-06-30
PCT/US2016/040108 WO2017004213A1 (en) 2015-06-30 2016-06-29 Btla fusion protein agonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021083133A Division JP2021113240A (ja) 2015-06-30 2021-05-17 Ｂｔｌａ融合タンパク質アゴニストおよびその使用

Publications (3)

Publication Number Publication Date
JP2018521999A JP2018521999A (ja) 2018-08-09
JP2018521999A5 true JP2018521999A5 (https=) 2019-06-06
JP7116285B2 JP7116285B2 (ja) 2022-08-10

Family

ID=57609132

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017568205A Active JP7116285B2 (ja) 2015-06-30 2016-06-29 Ｂｔｌａ融合タンパク質アゴニストおよびその使用
JP2021083133A Pending JP2021113240A (ja) 2015-06-30 2021-05-17 Ｂｔｌａ融合タンパク質アゴニストおよびその使用
JP2022115473A Active JP7559013B2 (ja) 2015-06-30 2022-07-20 Ｂｔｌａ融合タンパク質アゴニストおよびその使用
JP2023210069A Pending JP2024019529A (ja) 2015-06-30 2023-12-13 Ｂｔｌａ融合タンパク質アゴニストおよびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021083133A Pending JP2021113240A (ja) 2015-06-30 2021-05-17 Ｂｔｌａ融合タンパク質アゴニストおよびその使用
JP2022115473A Active JP7559013B2 (ja) 2015-06-30 2022-07-20 Ｂｔｌａ融合タンパク質アゴニストおよびその使用
JP2023210069A Pending JP2024019529A (ja) 2015-06-30 2023-12-13 Ｂｔｌａ融合タンパク質アゴニストおよびその使用

Country Status (13)

Country Link
US (3) US10961297B2 (https=)
EP (1) EP3317297A4 (https=)
JP (4) JP7116285B2 (https=)
KR (2) KR102669985B1 (https=)
CN (2) CN108026159B9 (https=)
AU (3) AU2016286108B2 (https=)
BR (1) BR112017028316A2 (https=)
CA (1) CA2990885A1 (https=)
EA (1) EA201890171A1 (https=)
IL (2) IL256383B2 (https=)
MX (1) MX2018000073A (https=)
SG (1) SG10201913567QA (https=)
WO (1) WO2017004213A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
KR102669985B1 (ko) 2015-06-30 2024-05-29 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 Btla 융합 단백질 작용제 및 이의 용도
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
US20030235580A1 (en) 2002-06-24 2003-12-25 Fen Zhang Amniotic membrane mediated delivery of bioactive molecules
EP1560593B1 (en) 2002-10-25 2016-04-20 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2006054961A2 (en) * 2004-11-12 2006-05-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US8188232B1 (en) 2004-11-15 2012-05-29 Washington University In St. Louis Compositions and methods for modulating lymphocyte activity
EP1833848A2 (en) * 2004-12-09 2007-09-19 Lajolla Institute for Allergy and Immunology Novel tnf receptor regulatory domain
WO2010006071A1 (en) * 2008-07-08 2010-01-14 La Jolla Institute For Allergy And Immunology Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use
US8349320B2 (en) * 2004-12-09 2013-01-08 La Jolla Institute For Allergy And Immunology Compositions and methods for modulating responses mediated or associated with BTLA activity
WO2007010692A1 (ja) 2005-07-19 2007-01-25 Japan Science And Technology Agency Ｈｖｅｍ及びｂｔｌａを標的とした炎症性腸疾患治療用医薬組成物及び治療方法
EP2097447A4 (en) 2006-11-15 2010-12-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
US8318662B2 (en) 2009-03-16 2012-11-27 Korea Institute Of Radiological & Medical Sciences Protein increasing cell infectivity of herpes simplex virus and use thereof
US8303952B2 (en) 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance
BR112012007875A2 (pt) 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
US9982023B2 (en) * 2011-11-15 2018-05-29 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders
EP3041494A4 (en) 2013-09-05 2017-10-18 Sanford-Burnham Medical Research Institute Modulation of gamma delta t cells
CA2981304C (en) 2015-04-02 2024-01-02 Memorial Sloan Kettering Cancer Center Tnfrsf14/hvem proteins and methods of use thereof
EP3288587A4 (en) 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
KR102669985B1 (ko) 2015-06-30 2024-05-29 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 Btla 융합 단백질 작용제 및 이의 용도
MX2018010295A (es) 2016-02-26 2019-06-06 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EP3470424B1 (en) * 2016-06-08 2025-04-23 Shanghai Jiao Tong University School of Medicine Sequence of antibody heavy chain constant region for enhancing agonist antibody activity
CN119950689A (zh) 2016-07-05 2025-05-09 北极星药业集团股份有限公司 使用精氨酸耗竭剂的组合癌症免疫疗法
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
US20200140547A1 (en) 2017-05-26 2020-05-07 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
EP3700536A4 (en) 2017-10-27 2021-11-17 Shanghai Yao Yuan Biotechnology Co., Ltd. COMPOSITIONS AND PROCEDURES FOR MODULATING IMMUNE REACTION BY ACTIVATING ALPHA-PROTEIN KINASE 1
EP3707163A4 (en) 2017-11-09 2021-08-18 The General Hospital Corporation POLYPEPTIDES ANTAGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
JP7337099B2 (ja) 2018-05-25 2023-09-01 アレクトル エルエルシー 抗ｓｉｒｐａ抗体およびその使用法
WO2019245817A1 (en) 2018-06-19 2019-12-26 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
BR112020026819A2 (pt) 2018-06-29 2021-04-20 Alector Llc anticorpos isolados, ácido nucleico, vetor, células hospedeiras, método de produção de um anticorpo, composição farmacêutica, métodos para tratar o câncer e para tratar uma doença e usos de um anticorpo
CN112955179A (zh) 2018-08-20 2021-06-11 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族多肽
EP3849666B1 (en) 2018-09-14 2026-04-15 Université de Lausanne Methods for modulating regulatory t cells and inhibiting tumor growth
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽

Similar Documents

Publication Publication Date Title
JP7746499B2 (ja) Ｃｌｅｃ９ａ結合物質およびその使用
JP2018521999A5 (https=)
CN111328286B (zh) Pd-1和pd-l1结合剂
US20240247047A1 (en) BTLA Fusion Protein Agonists and Uses Thereof
CN110546160A (zh) 靶向嵌合蛋白及其用途
JP2017533207A5 (https=)
CN118978595A (zh) 抗tim3单克隆抗体和嵌合抗原受体
US20250320302A1 (en) Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
HK40074138A (en) Anti-tim3 monoclonal antibodies and chimeric antigen receptors
HRP20210383T1 (hr) Kombinirana terapija za rak
Branschädel Analysis of molecular components essential for the formation of signaling-competent TNF-TNFR complexes
HK1161267A (en) TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS